文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

奥密克戎 XBB.1.5 疫苗对感染 SARS-CoV-2 奥密克戎 XBB 和 JN.1 变异株的有效性，前瞻性队列研究，荷兰，2023 年 10 月至 2024 年 1 月。

Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.

机构信息

Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.

出版信息

Euro Surveill. 2024 Mar;29(10). doi: 10.2807/1560-7917.ES.2024.29.10.2400109.

DOI:10.2807/1560-7917.ES.2024.29.10.2400109
PMID:38456217
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10986669/
Abstract

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23-55) in 18-59-year-olds and 50% (95% CI: 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8-2.6).

摘要

我们估计，在 2023 年 10 月 9 日至 2024 年 1 月 9 日期间，23895 名符合 XBB.1.5 疫苗接种条件的成年人中，此前至少接种过一次加强针的成年人中，针对自我报告的感染，SARS-CoV-2 奥密克戎 XBB.1.5 疫苗的有效性（VE）为 41%（95%CI：23-55），在 18-59 岁的人群中为 50%（95%CI：44-56）。测序数据表明，近期既往感染（OR=2.8；95%CI：1.2-6.5）和 XBB.1.5 疫苗接种（OR=1.5；95%CI：0.8-2.6）对 BA.2.86（包括 JN.1）变体的保护作用较低，但无统计学意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1238/10986669/73bbe58952dc/2400109-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1238/10986669/cac61f47d937/2400109-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1238/10986669/73bbe58952dc/2400109-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1238/10986669/cac61f47d937/2400109-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1238/10986669/73bbe58952dc/2400109-f2.jpg

相似文献

[1]
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.

Euro Surveill. 2024-3

[2]
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.

Lancet Infect Dis. 2024-9

[3]
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.

MMWR Morb Mortal Wkly Rep. 2023-2-3

[4]
BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.

Lancet Child Adolesc Health. 2023-7

[5]
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.

Lancet Infect Dis. 2023-7

[6]
Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.

J Med Virol. 2024-7

[7]
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.

J Infect Dis. 2024-8-16

[8]
Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.

medRxiv. 2024-3-29

[9]
Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.

J Virol. 2024-11-19

[10]
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.

Influenza Other Respir Viruses. 2024-10

引用本文的文献

[1]
Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives.

Mol Biol Rep. 2025-9-10

[2]
Pregnancy reduces COVID-19 vaccine immunity against novel variants.

NPJ Vaccines. 2025-8-13

[3]
Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.

Nat Commun. 2025-8-7

[4]
Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.

Nat Commun. 2025-7-15

[5]
Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults.

JAMA Netw Open. 2025-6-2

[6]
Immune modulation: the key to combat SARS-CoV-2 induced myocardial injury.

Front Immunol. 2025-5-14

[7]
Using surveillance data to evaluate the effectiveness of inactivated/mRNA COVID-19 vaccine boosters in preventing fatal outcomes among severe COVID-19 cases during the current ambit of SARS-CoV-2 XBB and JN.1 variant circulation.

Front Public Health. 2025-5-14

[8]
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.

Influenza Other Respir Viruses. 2025-3

[9]
Prospective cohort study of fatigue before and after SARS-CoV-2 infection in the Netherlands.

Nat Commun. 2025-3-4

[10]
XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants.

Front Immunol. 2025-2-17

本文引用的文献

[1]
Cohort profile: an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - the VAccine Study COVID-19 (VASCO).

BMJ Open. 2024-10-14

[2]
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.

Lancet Infect Dis. 2024-9

[3]
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.

MMWR Morb Mortal Wkly Rep. 2024-2-1

[4]
Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.

Lancet Infect Dis. 2024-2

[5]
Virological characteristics of the SARS-CoV-2 JN.1 variant.

Lancet Infect Dis. 2024-2

[6]
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023.

Euro Surveill. 2024-1

[7]
Covid-19: WHO adds JN.1 as new variant of interest.

BMJ. 2023-12-21

[8]
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.

Nature. 2023-12

[9]
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study.

Int J Infect Dis. 2023-8

[10]
Sequencing directly from antigen-detection rapid diagnostic tests in Belgium, 2022: a gamechanger in genomic surveillance?

Euro Surveill. 2023-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索